By Jason Derry --
Cytos Biotechnology AG has granted a worldwide, exclusive license to Novartis to develop, manufacture, and commercialize its therapeutic vaccine for nicotine addiction, CYT002-NicQb. The vaccine is currently in Phase II clinical development. Cytos may receive upfront and milestone payments, as well as royalty payments, based on the successful commercial launch and sales of CYT002-NicQb. The agreement is subject to regulatory review before final approval. The press release can be viewed here.
Comments